FDA Advisory Committee rejects Sefelsa(Depomed)as a treatment for Menopause

Depomed, Inc. has announced that the Reproductive Health Drugs Advisory Committee (RHDAC) of the FDA voted 2-12 against approval for Sefelsa, Depomed's investigational, oral, twice daily formulation of gabapentin, to treat moderate to severe vasomotor symptoms due to Menopause. Sefelsa is the proposed trade name for the medication and was formerly referred to as Serada.